Effectiveness of Rapid Guideline-directed Medical Therapies initiation Strategy at Heart failure Clinic, King narai hospital.

Authors

  • Sakolrat Hauythan Medical Physician, Senior Professional Level. Heart Failure Clinic, King narai hospital, Lopburi Province.
  • Waranya kedchai Professional Nurse, Professional Level. Heart Failure Clinic, King narai hospital, Lopburi Province.

Keywords:

Rapid Guideline-directed Medical Therapies initiation Strategy, Acute heart failure, Titration to Maximum Tolerated Dose

Abstract

This study employed a quasi-experimental, one-group pretest–posttest design to evaluate the effectiveness of a rapid and intensive titration protocol for the treatment of heart failure with reduced ejection fraction (HFrEF) at the Heart Failure Clinic, Phra Narai Maharaj Hospital. The sample comprised 34 patients with heart failure, selected through simple random sampling. The intervention consisted of a rapid and intensive titration guideline implemented in the clinic. Data collection instruments included a personal information questionnaire, physical examination and laboratory record forms, medication titration records based on guideline-directed medical therapy (GDMT), time to achieve target GDMT, records of adverse drug events, and hospital readmission data. Data were analyzed using descriptive statistics and paired t-test.

Results showed that, following the application of the rapid and intensive titration protocol, most participants achieved full implementation of GDMT. The majority reached the maximum tolerated dose (% target dose) within 6–10 weeks across the three main drug groups. No severe adverse drug events were observed during the treatment period. Left ventricular ejection fraction (LVEF) significantly improved from a baseline mean of 23.67 ± 6.81% to 35.20 ± 9.57% after 16 weeks of treatment (p < .005).

The rapid and intensive titration protocol in the heart failure clinic enabled most patients to safely achieve target medication doses, with a low incidence of adverse effects. These findings support the feasibility and effectiveness of adopting this approach in routine clinical practice.

Downloads

Download data is not yet available.

References

Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020; 1342 – 56. https://doi.org/10.1002/ejhf.1858

Chaimongkol O, Phuwanun S, Phumiwatana S. The role of nurses in the care of patients with heart failure at the outpatient department. Vajira Nursing Journal. 2022;24(1):75–95.

Laothavorn P, Hengrussamee K, Kanjanavanit R, Moleerergpoom W, Laorakpongse D, Pachirat O, et al. Thai acute decompensated heart failure registry (Thai ADHERE). CVD Prev Control. 2010;5(3):89–95.

Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5(6):720–726. https://doi.org/10.1161/CIRCHEARTFAILURE.111.966366

King narai Hospital, Medical Record Department. Heart failure statistics. Lopburi: King Narai Hospital; 2024.

Metra M, Heart Failure Association of the ESC. Pre -discharge and early post-discharge management of patients hospitalized for acute heart failure: a scientific statement by the Heart Failure Association of the ESC. Eur J Heart Fail. 2023. https://doi.org/10.1002/ejhf.2888

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895 – e1032. https://doi.org/10.1161

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032. https://doi.org/10.1161

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj

Heart Failure Council of Thailand. 2019 heart failure guideline. Bangkok: The Heart Association of Thailand under the Royal Patronage; 2019.

Ashley G. STRONG-HF: High-intensity care leads to higher doses of guideline heart failure therapy [Internet]. MH Life Sciences; 2024 [cite 2024 Jan 5] Available from: https://www.pharmacytimes.com/

McCullough PA, et al. Efficacy, safety and mechanistic impact of a heart failure guideline - directed medical therapy clinic. J Am Coll Cardiol. 2024;83(3):295–305.

Sharma A, Smith J, Lee K. Sociodemographic disparities in the use of GLP-1 receptor agonists and SGLT - 2 inhibitors among US adults with type 2 diabetes: NHANES 2005 - March 2020. https://doi.org/10.1101/2023.03.30.23287965v1

European Society of Cardiology. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.

European Society of Cardiology. Cardio protective drugs: Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs) [Internet]. 2021. https://www.escardio.org/Education/

Niriayo YL, Asgedom SW, Demoz GT, Gidey K. Treatment optimization of beta - blockers in chronic heart failure therapy. Sci Rep. 2020;10(1):15903. https://doi.org/10.1038/s41598 - 020 - 72836-4

Packer M, McMurray JJV, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077

Gupta A. The use of β - blockers in heart failure with reduced ejection fraction. J Clin Med. 2021;10(7):2020. https://doi.org/10.3390/jcm10072020

Worku DK, Abegaz TM, Belayneh YM, Mekuria AN. Spironolactone and eplerenone use in heart failure patients: A systematic review and meta - analysis. Integr Pharm Res Pract. 2020;9:31–42. https://doi.org/10.2147/IPRP.S231495

Mebazaa A, Davison BA, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M. Safety, tolerability and efficacy of up - titration of guideline -directed medical therapies for acute heart failure (STRONG-HF): a multinational, open - label, randomised, trial. Lancet. 2022;400(10367):1938–52. https://doi.org/10.1016/S0140-6736(22)02076-1

Chrysafides JA, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2021;400(10365):1938–52. https://doi.org/10.1016/S0140-6736(22)02076 – 1

Veltmann C, Angermann CE, Bollmann A, Butler J, Drexler H, Pieske B. Continued reverse remodeling of the left ventricle in de novo heart failure with reduced ejection fraction after 90 days of optimized GDMT: Insights from the STRONG - HF trial. Pace - CME. 2024. https://pace - cme.org/news/

Downloads

Published

26-08-2025

How to Cite

1.
Hauythan S, kedchai W. Effectiveness of Rapid Guideline-directed Medical Therapies initiation Strategy at Heart failure Clinic, King narai hospital. Singburi Hosp J [internet]. 2025 Aug. 26 [cited 2026 Jan. 7];34(1-2):B33-47. available from: https://he01.tci-thaijo.org/index.php/shj/article/view/279783

Issue

Section

Research Articles